Call us today 212-583-0100

ENZO Life Sciences Launches New Advanced Amplification Technology for Gene Expression Analysis Studies

New York, NY, November 11, 2004 –Enzo Biochem (NYSE: ENZ) announced today that its wholly owned subsidiary, Enzo Life Sciences, has launched a new amplification method aimed at improving gene expression data derived from microarray experiments.
The relatively large amounts of RNA sample required to carry out microarray analysis often cannot be obtained easily from many common sources, especially those derived from biopsies or microdissection.  Additionally, rare and valuable RNA samples require preservation by researchers for future studies.  With Enzo’s new amplification system, researchers relying on microarray expression data may now obtain enhanced results, efficiently amplifying the relevant messenger RNA sequences while faithfully maintaining sample integrity, even after extensive amplification. 
The new amplification method has the potential to amplify either the antisense or sense strand of RNA, thereby providing versatility for application to any type of microarray. The amplification method is being marketed by Enzo Life Sciences in various formats, enabling researchers to select the strand to be amplified, as well as select modules for achieving the level of sensitivity desired. The first product, now on the market, amplifies the antisense strand of RNA.
Dr. Shui Quing Ye, MD Ph.D at Johns Hopkins University Medical School, Division of Pulmonary and Critical Care said, “We tried several other amplification methods and Enzo’s method stands out. Enzo’s method yields results consistent with an experiment that requires no amplification, as is the case when one has abundant levels of starting material.”
Commented Dafeng Zhou, Ph.D. at Monsanto Company, St. Louis: "The Enzo kit has produced good results with the plant samples that we have tested. Although we found Enzo's procedure to require more hands-on time and detail than other amplification methods, in science you often need to spend a little more time and effort to obtain high quality results."
“Offering this breakthrough technology to the research community in a simple-to-use kit format represents another contribution from Enzo in the standardization of microarray expression data,” said Jim Chinitz, Enzo Life Sciences Vice President of Business Development. “We embarked on this project in response to our customers telling us that their most commonly used amplification methods all suffer from the same insufficiencies.  Other alternative methods recently introduced into the marketplace emphasize convenience, but they significantly compromise the quality of the data produced.  However, by combining Enzo’s new amplification method with our Company’s gold standard biotin RNA labeling chemistry, we have produced a product with sensitivity down to 5 nanograms, and theoretically down to a single cell of input RNA.  The yield of material along with the maintenance of the sample integrity is the key advantage, as evidenced by very low 3’5’ ratios for long and short genes represented on a microarray.”
Enzo’s BioArray™ RNA Amplification and Labeling System supplies all reagents for the amplification and biotin labeling of antisense RNA for use with eukaryotic gene expression microarrays.  The system includes a cDNA synthesis and in vitro transcription module and the gold standard biotin-labeled ribonucleotide mix.  Advantages over commercially available methods include: the use of 2 biotin-labeled nucleotides for maximum incorporation and signal, and the maintenance of sample integrity through multiple rounds of amplification as evidenced by excellent 3’ 5’ ratios.  These attributes provide genetic researchers with reproducible and standardized results experiment to experiment, project to project and lab to lab.
About Enzo
Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis, with over 200 patents worldwide, are sold to the life sciences market throughout the world. The Company’s therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis B and hepatitis C infection and for Crohn’s Disease. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. For more information visit our website
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.